GSK and NEOMED call for proposals for innovative early stage human therapeutic projects in Quebec
GSK and NEOMED are calling on Quebec-based researchers to submit their innovative projects in early drug discovery for potential funding under the GSK and NEOMED $2 million Discovery Fund.
GlaxoSmithKline Inc. (GSK) and the NEOMED Institute (NEOMED) are inviting researchers from Quebec-based academic centers or research institutes to submit an application for potential funding to help advance their innovative early stage human therapeutic research.
This first formal call for proposals follows GSK and NEOMED’s launch in 2017 of a $2 million Discovery Fund dedicated to the translation of innovative Quebec-based therapeutic research into new medicines for the benefit of patients.
The Discovery Fund will provide selected projects with seed funding (estimated to be approximately $100k/per project/year) to advance the efforts of one or more promising Quebec investigators conducting innovative research to the discovery of new medicines in any therapeutic area of unmet medical need. In addition to funding, successful candidates will benefit from ongoing mentorship and expert counsel provided by senior GSK and NEOMED scientists, and the use of NEOMED’s state-of-the-art facilities and network of industry service providers. It is expected that many of these projects will be at an early development stage and that the use of the funds will be to support target validation through lead drug candidate selection.
“GSK is committed to supporting Quebec’s life sciences sector and is excited about the opportunity to help accelerate innovation among the province’s internationally recognized scientific community through the Discovery Fund,” said Carolyn Buser-Doepner, Vice President and Global Head of Discovery Partnerships with Academia, GSK. “We are proud to work in collaboration with leading researchers in Quebec and across the globe to help translate scientific discoveries into new and better treatment options to address patient need.”
“Our discovery collaboration with GSK to identify and fund translational research based on discoveries emanating from Quebec universities and research centres is perfectly aligned with our mission to advance great scientific discoveries towards meaningful therapeutic options for patients.” noted Donald Olds, President & CEO of NEOMED Institute.